189 related articles for article (PubMed ID: 19427850)
1. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
Zhan Y; Counelis GJ; O'Rourke DM
Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
[TBL] [Abstract][Full Text] [Related]
2. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
Zhan Y; O'Rourke DM
Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697
[TBL] [Abstract][Full Text] [Related]
3. SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration.
Kapoor GS; O'Rourke DM
Oncogene; 2010 Jul; 29(29):4130-44. PubMed ID: 20473329
[TBL] [Abstract][Full Text] [Related]
4. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
Kapoor GS; Zhan Y; Johnson GR; O'Rourke DM
Mol Cell Biol; 2004 Jan; 24(2):823-36. PubMed ID: 14701753
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.
Kapoor GS; Christie A; O'Rourke DM
Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042
[TBL] [Abstract][Full Text] [Related]
7. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Miyamoto D; Miyamoto M; Takahashi A; Yomogita Y; Higashi H; Kondo S; Hatakeyama M
Oncogene; 2008 Jun; 27(25):3508-15. PubMed ID: 18223690
[TBL] [Abstract][Full Text] [Related]
8. Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion.
Feng H; Liu KW; Guo P; Zhang P; Cheng T; McNiven MA; Johnson GR; Hu B; Cheng SY
Oncogene; 2012 May; 31(21):2691-702. PubMed ID: 21996738
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
[TBL] [Abstract][Full Text] [Related]
10. STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Puram SV; Yeung CM; Jahani-Asl A; Lin C; de la Iglesia N; Konopka G; Jackson-Grusby L; Bonni A
J Neurosci; 2012 Jun; 32(23):7806-18. PubMed ID: 22674257
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
12. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
Li L; Chakraborty S; Yang CR; Hatanpaa KJ; Cipher DJ; Puliyappadamba VT; Rehman A; Jiwani AJ; Mickey B; Madden C; Raisanen J; Burma S; Saha D; Wang Z; Pingle SC; Kesari S; Boothman DA; Habib AA
Oncogene; 2014 Aug; 33(33):4253-64. PubMed ID: 24077285
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Feng H; Hu B; Jarzynka MJ; Li Y; Keezer S; Johns TG; Tang CK; Hamilton RL; Vuori K; Nishikawa R; Sarkaria JN; Fenton T; Cheng T; Furnari FB; Cavenee WK; Cheng SY
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3018-23. PubMed ID: 22323579
[TBL] [Abstract][Full Text] [Related]
15. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
16. Signal Peptide Peptidase, Encoded by HM13, Contributes to Tumor Progression by Affecting EGFRvIII Secretion Profiles in Glioblastoma.
Wei JW; Cai JQ; Fang C; Tan YL; Huang K; Yang C; Chen Q; Jiang CL; Kang CS
CNS Neurosci Ther; 2017 Mar; 23(3):257-265. PubMed ID: 28198167
[TBL] [Abstract][Full Text] [Related]
17. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
18. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
de la Iglesia N; Konopka G; Puram SV; Chan JA; Bachoo RM; You MJ; Levy DE; Depinho RA; Bonni A
Genes Dev; 2008 Feb; 22(4):449-62. PubMed ID: 18258752
[TBL] [Abstract][Full Text] [Related]
19. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
[TBL] [Abstract][Full Text] [Related]
20. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
